16-Jan-2026
PRNewswire (Thu, 8-Jan 7:00 AM ET)
PRNewswire (Wed, 5-Nov 7:00 AM ET)
InMode Appoints Michael Dennison as President of North America
PRNewswire (Mon, 3-Nov 8:05 AM ET)
InMode to Participate in Upcoming Investor Conferences
PRNewswire (Thu, 30-Oct 8:30 AM ET)
InMode Expects Strong Q3 Results with Gross Margins up to 79%—FY 2025 Guidance Reaffirmed
Market Chameleon (Thu, 9-Oct 4:17 AM ET)
History Shows INMD could rally into earnings
Market Chameleon (Thu, 24-Oct 9:07 AM ET)
A Stock Rise in INMD has History on Its Side
Market Chameleon (Fri, 26-Jul 9:23 AM ET)
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.
Inmode Ltd. - trades on the NASDAQ stock market under the symbol INMD.
As of January 16, 2026, INMD stock price declined to $13.94 with 843,638 million shares trading.
INMD has a beta of 0.71, meaning it tends to be less sensitive to market movements. INMD has a correlation of 0.18 to the broad based SPY ETF.
INMD has a market cap of $849.21 million. This is considered a Small Cap stock.
Last quarter Inmode Ltd. - reported $93 million in Revenue and $.38 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.06.
In the last 3 years, INMD traded as high as $48.25 and as low as $13.14.
The top ETF exchange traded funds that INMD belongs to (by Net Assets): IEFA, SCZ, IXUS, IZRL, AVDV.
INMD has underperformed the market in the last year with a price return of -15.9% while the SPY ETF gained +18.1%. INMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.4% and -5.8%, respectively, while the SPY returned +5.0% and +1.2%, respectively.
INMD support price is $13.79 and resistance is $14.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INMD shares will trade within this expected range on the day.